Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2008

View Archived Issues

Preclinical profile of Pfizer's novel CRF1 receptor antagonist CP-376395

Recent patents divulge novel analgesic agents

Novel antimicrobial agents reported in recent Genesis and Orchid patents

Recent patents disclose novel treatment options for obesity and metabolic disorders

New pegaptanib-encapsulated microspheres provide sustained drug release in vitro and in vivo

Impaired cognition in diabetes associated with increased cortisol levels

XenoPort and GSK report positive results from phase III trial of XP-13512

Everolimus improves progression-free survival in advanced kidney cancer

MedImmune to support ACIP recommendations for influenza vaccinations

First European filing for lubiprostone in U.K.

Not approvable letter for Zyprexa long-acting injection in schizophrenia

Nexium approved for use in children aged 1-11 years

CHMP requests further clinical data before approving Ceplene for AML

Enrollment completed in proof-of-concept trial for MB-07803 in type 2 diabetes

Serenex and the NCI enter clinical trial agreement for Hsp90 inhibitor SNX-5422

Calorie restriction protects against carcinogenesis via Nrf2 signaling

Preclinical profile of GRL-8234 reported by Comentis

ZARS is granted marketing authorization for Rapydan in 11 European countries

PAION reports results from first-in-man escalating-dose study of Solulin

Phase II clinical trial shows efficacy of AL-108 in cognition and memory impairment

Alpharma submits NDA for Embeda

AstraZeneca submits sNDA for Seroquel XR for major depressive disorder

Dosing commences in phase I AZX-100 trial in dermal/hypertrophic scarring

Ferring submits NDA for prostate cancer drug candidate degarelix

FDA approves Aloxi injection for prevention of postoperative nausea and vomiting

FDA approves Pristiq as therapy for adults with major depressive disorder

Vasolan tablets approved for atrial fibrillation/flutter and tachycardia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...